Business
Telo Genomics Presents Positive Results in Assessing MRD in Multiple Myeloma Patients at the International Myeloma Society Annual Meeting
Toronto, Ontario--(Newsfile Corp. - October 12, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB:...
About this update from Telo Genomics Corp.
[{"type":"text","content":"Telo Genomics Presents Positive Results in Assessing MRD in Multiple Myeloma Patients at the International Myeloma Society Annual MeetingToronto, Ontario--(Newsfile Corp. - October 12, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the \"Company\" or \"TELO\") is pleased to announce that it has participated in the International Myeloma Society (\"IMS\") annual meeting that took place in Athens, Greece during the last week of September 2023. Telo presented positive results in assessing minimal residual disease (\"MRD\") in multiple myeloma (\"MM\"). The data presented demonstrated repeatable sensitivity three-fold higher than what is currently being used in clinical practice. The presented results will be published in the journal of Clinical Lymphoma, Myeloma & Leukemia.Telo's MRD test pioneers an innovative, proprietary and minimally invasive technology with the potential to facilitate MRD assessment in most MM patients. The test is designed to monitor MM patients' performance post-treatment to predict patients' relapse or to guide an informed decision to terminate maintenance therapy for patients who remain in remission, a critical unmet need in the clinic. The data presented at the IMS meeting represents the initial phase of an ongoing prospective clinical trial to monitor disease progression in post-treatment patients, by measuring and profiling MRD in these patients using Telo's proprietary technology. The clinical trial is being conducted in collaboration with McGill University and the Jewish General Hospital in Montreal, Canada. The trial is listed on the website of the National Library of Medicine (clinicaltrials.gov): NCT05530096 (https://clinicaltrials.gov/ct2/show/NCT05530096).\"We were excited to present Telo's MRD interim results at the recent IMS annual meeting,\" said Sherif Louis, TELO's President & CTO. \"The IMS annual meeting is the highest caliber myeloma meeting globally, and we were impressed with the level of engagement related to MRD at our booth. Our results were very well received by the world's top myeloma treating physicians and key opinion leaders.\"About MRDMonitoring MRD in oncology is emerging as an important prognostic tool for assessing the depth of a patient's response to treatment; it can also help in identifying patients at higher risk of relapse and potentially guide respons...